IGF::OT::IGF FAST-PS THIRD ADMINISTRATIVE TASK - New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum Disorders (FAST-PS)
IGF::OT::IGF FAST-PS THIRD ADMINISTRATIVE TASK - New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum Disorders (FAST-PS)
批准号:
8947310
负责人:
JEFFREY LIEBERMAN
金额:
$11.78万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-24 至 2015-09-23
关键词:
AgonistAnhedoniaBiological MarkersCertificate of ConfidentialityClinicalClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesCommunicationCommunitiesContractsDevelopmentDimensionsDiseaseEnrollmentFeasibility StudiesFutureGoalsHumanInformation SystemsInformed ConsentInstitutional Review BoardsInterventionManuscriptsMeasurementMeasuresMedicineModalityMolecularNational Institute of Mental HealthPhasePhysiologicalPilot ProjectsPreparationProtocols documentationPsychopathologyPublicationsRegistriesReportingResearch InfrastructureScheduleSiteSupport ContractsTeleconferencesTestingTrainingUnited States National Institutes of HealthUnited States National Library of MedicineWritingabstractingcognitive functionnovelprotocol developmentreceptorsocialtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Administrative Task Description: The effort needed to support contract start-up and management, including developing draft protocols, communication with NIH and other components of the FAST-PS effort, and preparation of Minutes, Quarterly, and Final Task Order Reports, and all other reports and deliverables listed in the Reporting Requirements/Deliverables attachment. Study 1 Description/abstract: This initiative seeks to expeditiously test and analyze a novel intervention (i.e., compound) and their molecular and/or clinical targets for treating clinical dimensions of psychopathology (e.g., anhedonia, cognitive function, social engagement) associated with traditional psychotic spectrum disorders. The overall goal of this project shall be to evaluate the ability of an agonist to reverse alterations in healthy humans. These modalities could provide information regarding the degree of target engagement association with the agent. If the agent significantly reverses effects on measurements, it would suggest availability of a predictive physiological marker to assess target engagement of novel compounds targeting the receptor and help facilitate future agent related clinical development. The study will be an initial 1st Phase Pilot Feasibility study/clinical trial to validate the feasibility, reliability, and comparability of the protocol and proposed biomarker measure tools to be used in a potential 2nd Phase POCM clinical trial
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum
-
批准号:9004343
-
项目类别:
-
资助金额:$447.91万
-
财政年份:2015
-
负责人:JEFFREY LIEBERMAN
-
依托单位:
New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum
-
批准号:8836464
-
项目类别:
-
资助金额:$128.74万
-
财政年份:2013
-
负责人:JEFFREY LIEBERMAN
-
依托单位:
CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVES
-
批准号:7542403
-
项目类别:
-
资助金额:$250.4万
-
财政年份:1999
-
负责人:JEFFREY LIEBERMAN
-
依托单位:--
海外基金